---
title: "Hong Kong Healthcare Stocks Split: Far Eastern Pharma's FDA Gamble vs. Real Estate Quagmire"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/303372800.md"
description: "Far Eastern Pharma advances ocular drug trials while Poly Platinum Medical accelerates hospital acquisitions. Morgan Stanley slashes Haoya Medical's target price as New Ming China's audit delay triggers suspension. Convergence Tech's 75% profit surge highlights sector classification chaos."
datetime: "2026-10-28T10:14:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/303372800.md)
  - [en](https://longbridge.com/en/news/303372800.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/303372800.md)
generator: "portal-rs"
---

# Hong Kong Healthcare Stocks Split: Far Eastern Pharma's FDA Gamble vs. Real Estate Quagmire

Far Eastern Pharma (0512.HK) is betting big on its GPN00833 nano-suspension eye drops. The specialty drugmaker completed first patient dosing in Phase III trials for post-cataract inflammation last week, with FDA submission already filed—a rare bright spot in Hong Kong's biotech sector.

Poly Platinum Medical (1515.HK) took a different approach, overhauling its hospital acquisition strategy in early October. The move sparked a 5% intraday surge as investors weighed scalability against profitability in China's fragmented healthcare market.

MicroPort Scientific (0853.HK) granted 17.8 million stock options to management, signaling confidence in its cardiovascular device pipeline despite near-term market headwinds. The move drew mixed reactions from analysts tracking its U.S. market entry prospects.

Haoya Medical (6078.HK) faced harsher realities when Morgan Stanley slashed its target price by 20% in late September, triggering a 5% single-day plunge. The tumor hospital operator's premium valuation now faces intense scrutiny amid pricing pressures.

The sector's identity crisis became stark with New Ming China (2699.HK)—a property developer—remaining suspended over delayed financial reporting. Meanwhile, Convergence Tech (1729.HK) reported 75% interim profit growth from server sales, underscoring how loosely defined "healthcare" tags can mislead investors.

### Related Stocks

- [01515.HK](https://longbridge.com/en/quote/01515.HK.md)
- [00853.HK](https://longbridge.com/en/quote/00853.HK.md)
- [00512.HK](https://longbridge.com/en/quote/00512.HK.md)
- [06078.HK](https://longbridge.com/en/quote/06078.HK.md)
- [01729.HK](https://longbridge.com/en/quote/01729.HK.md)
- [02699.HK](https://longbridge.com/en/quote/02699.HK.md)

## Related News & Research

- [Time Interconnect Technology Reports Share Buyback in HKEX Next-Day Disclosure Return](https://longbridge.com/en/news/306260193.md)
- [Hygeia Healthcare Files Next-Day Disclosure Return With HKEX Announcing Share Buyback](https://longbridge.com/en/news/306251337.md)
- [Hygeia Healthcare Files Next-Day Disclosure With HKEX Announcing Share Buyback](https://longbridge.com/en/news/305952086.md)
- [Time Interconnect Technology (SEHK:1729) Could Be 65% Undervalued After HK$500 Million Buyback](https://longbridge.com/en/news/305220160.md)
- [Time Interconnect Technology Files HKEX Return Disclosing Share Buyback](https://longbridge.com/en/news/304995279.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**